Edward M. Md Kaye Sells 10,000 Shares of Sarepta Therapeutics, Inc. (SRPT) Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Edward M. Md Kaye sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $410,000.00. Following the completion of the transaction, the director now directly owns 62,471 shares of the company’s stock, valued at $2,561,311. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at 42.48 on Monday. The firm’s market cap is $2.33 billion. Sarepta Therapeutics, Inc. has a 12-month low of $22.61 and a 12-month high of $63.73. The stock’s 50 day moving average price is $33.69 and its 200-day moving average price is $32.07.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. The firm’s revenue was up 350000.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.19) EPS. On average, analysts predict that Sarepta Therapeutics, Inc. will post ($0.94) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was first published by [[site]] and is owned by of [[site]]. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at [[permalink]].

SRPT has been the subject of several analyst reports. Oppenheimer Holdings, Inc. set a $76.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research note on Sunday, March 26th. SunTrust Banks, Inc. raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the company from $30.00 to $30.97 in a research note on Wednesday, April 5th. Jefferies Group LLC reissued a “hold” rating and issued a $27.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, April 6th. Robert W. Baird reissued an “outperform” rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, April 23rd. Finally, Vetr cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $37.67 target price for the company. in a research note on Monday, April 24th. Eight equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $61.28.

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after buying an additional 5,175,193 shares during the period. Camber Capital Management LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter worth about $39,960,000. State Street Corp boosted its stake in shares of Sarepta Therapeutics by 21.2% in the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after buying an additional 559,342 shares during the period. Norges Bank bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $11,181,000. Finally, Pinnacle Associates Ltd. bought a new stake in shares of Sarepta Therapeutics during the first quarter worth about $10,706,000. 73.09% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).